ISIS PHARMACEUTICALS INC DEL - NOTE 1.000%11/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2021

Type / Class
Debt / NOTE 1.000%11/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of ISIS PHARMACEUTICALS INC DEL - NOTE 1.000%11/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2021 Q4 $0 $0 -$49,938,000 0
2021 Q3 $49,835,500 $49,938,000 +$366,667 100.0% 18
2021 Q2 $49,494,500 $49,785,000 -$245,029,570 100.06% 22
2021 Q1 $291,876,400 $299,156,298 +$81,055,775 101.51% 41
2020 Q4 $214,660,400 $235,351,756 +$9,737,108 108.43% 41
2020 Q3 $210,410,600 $220,039,953 +$1,735,345 103.33% 43
2020 Q2 $207,823,100 $231,621,765 +$884,434 110.3% 48
2020 Q1 $207,530,234 $210,897,141 +$12,815,532 101.22% 49
2019 Q4 $194,112,610 $223,004,087 -$464,181,582 114.48% 52
2019 Q3 $603,301,410 $689,201,293 +$48,576,904 114.12% 59
2019 Q2 $559,810,772 $663,662,866 -$31,257,430 118.5% 59
2019 Q1 $568,921,910 $769,134,948 +$30,791,119 135.19% 58
2018 Q4 $552,325,972 $592,038,514 +$18,413,075 107.28% 49
2018 Q3 $516,120,400 $544,422,589 -$7,103,121 105.25% 44
2018 Q2 $523,679,400 $514,053,375 -$31,956,544 98.23% 46
2018 Q1 $555,020,400 $550,590,387 -$25,155,394 99.04% 53
2017 Q4 $581,359,400 $615,025,630 -$10,883,086 105.61% 50
2017 Q3 $591,689,000 $627,229,697 +$26,831,916 105.88% 42
2017 Q2 $565,996,310 $601,902,851 -$21,072,647 106.1% 44
2017 Q1 $587,366,011 $566,481,242 +$8,318,121 96.45% 44
2016 Q4 $577,411,009 $587,717,522 +$209,944,883 101.5% 44
2016 Q3 $371,321,000 $346,421,691 -$59,401,536 93.29% 39
2016 Q2 $458,620,000 $325,189,980 -$5,571,506 70.86% 44
2016 Q1 $461,458,000 $421,344,894 +$26,191,596 91.13% 39
2015 Q4 $437,645,000 $491,457,000 +$448,400,000 112.51% 40